Cancer Communications >

2024 , Vol. 44 >Issue 2: 278 - 281

DOI: https://doi.org/10.1002/cac2.12512

Association of previously irradiated stable brain metastases with outcomes of atezolizumab-treated non-small cell lung cancer: A pooled analysis of individual patient data from three randomized trials

  • Tiantian Guo 1,2,3,4 ,
  • Yue Zhou 1,2,3,4 ,
  • Fei Liang 5 ,
  • Zezhou Wang 2,6 ,
  • Vincent Bourbonne 7 ,
  • Lukas Käsmann 8 ,
  • Nora Sundahl 9 ,
  • Abraham Jing-Ching Wu 10 ,
  • Jianjiao Ni , 1,2,3,4 ,
  • Zhengfei Zhu , 1,2,3,4,11
Expand
  • 1. Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, P. R. China
  • 2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, P. R. China
  • 3. Shanghai Clinical Research Center for Radiation Oncology, Shanghai, P. R. China
  • 4. Shanghai Key Laboratory of Radiation Oncology, Shanghai, P. R. China
  • 5. Department of Biostatistics, Zhongshan Hospital, Fudan University, Shanghai, P. R. China
  • 6. Department of Cancer Prevention, Fudan University Shanghai Cancer Center, Shanghai, P. R. China
  • 7. Radiation Oncology Department, University Hospital, Brest, France
  • 8. Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany
  • 9. Department of Radiation Oncology, AZ Groeninge, Kortrijk, Belgium
  • 10. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
  • 11. Institute of Thoracic Oncology, Fudan University, Shanghai, P. R. China
nijianjiao8@sina.com
fuscczzf@163.com

Received date: 03 Jul 2023

Revised date: 10 Dec 2023

Accepted date: 12 Dec 2023

Published date: 20 Feb 2024

Copyright

2023 2023 The Authors. Cancer Communications published by JohnWiley & Sons Australia, Ltd on behalf of SUN YAT-SEN UNIVERSITY CANCER CENTER.
Fold

Cite this article

Tiantian Guo , Yue Zhou , Fei Liang , Zezhou Wang , Vincent Bourbonne , Lukas Käsmann , Nora Sundahl , Abraham Jing-Ching Wu , Jianjiao Ni , Zhengfei Zhu . Association of previously irradiated stable brain metastases with outcomes of atezolizumab-treated non-small cell lung cancer: A pooled analysis of individual patient data from three randomized trials[J]. Cancer Communications, 2024 , 44(2) : 278 -281 . DOI: 10.1002/cac2.12512

References

Publishing order | Descend order by publishing year | Descend order by cited within
1
ErnaniV, Stinchcombe TE. Management of Brain Metastases in Non-Small-Cell Lung Cancer. J Oncol Pract. 2019;15(11):563–570.

2
HendriksLEL, HenonC, AuclinE, Mezquita L, FerraraR, Audigier-ValetteC, et al. Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors. J Thorac Oncol. 2019;14(7):1244–1254.

3
DudnikE, Moskovitz M, DaherS, ShamaiS, Hanovich E, GrubsteinA, et al. Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data. Lung Cancer. 2018;126:217–223.

4
ArbourKC, Mezquita L, LongN, RizviH, AuclinE, NiA, et al. Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. J Clin Oncol. 2018;36(28):2872–2878.

5
MountziosG, de Toma A, EconomopoulouP, FriedlaenderA, BaniniM, Lo RussoG, et al. Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy. Clin Lung Cancer. 2021;22(2):e180–e192.

6
WestH, McCleod M, HusseinM, MorabitoA, Rittmeyer A, ConterHJ, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(7):924–937.

7
JotteR, Cappuzzo F, VynnychenkoI, StroyakovskiyD, Rodríguez-Abreu D, HusseinM, et al. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial. J Thorac Oncol. 2020;15(8):1351–1360.

8
SocinskiMA, JotteRM, CappuzzoF, Orlandi F, StroyakovskiyD, NogamiN, et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018;378(24):2288–2301.

9
ChenH, FengY, ZhouY, Tao Y, TangL, ShiY. Brain metastases and immune checkpoint inhibitors in non-small cell lung cancer: a systematic review and meta-analysis. Cancer Immunol Immunother. 2022;71(12):3071–3085.

10
GuoT, ChuL, ChuX, YangX, LiY, ZhouY, et al. Brain metastases, patterns of intracranial progression, and the clinical value of upfront cranial radiotherapy in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors. Transl Lung Cancer Res. 2022;11(2):173–187.

Options
Outlines

/

〈 〉